Role of concentration-dependent plasma protein binding in disopyramide disposition

  • Peter J. Meffin
  • Edward W. Robert
  • Roger A. Winkle
  • Sandra Harapat
  • Flora A. Peters
  • Donald C. Harrison


Plasma disopyramide concentration-time data and plasma protein binding measurements were obtained in 12 patients requiring disopyramide for suppression of their cardiac arrhythmias. The fraction of disopyramide unbound to plasma proteins varies from approximately 0.19 to 0.46 over the therapeutic range of total plasma concentrations (2–8 mg/liter). Data from single and multiple intravenous doses were analyzed using two models based on the hypothesis either that clearance is independent of the total disopyramide plasma concentration (total clearance model) or that clearance is independent of the concentration of disopyramide unbound to plasma proteins (free clearance model). This analysis indicates that only the free clearance model satisfactorily describes the data as a linear system. Using the free clearance model and data obtained from single doses, multiple intravenous infusions were designed for each patient which would rapidly attain and maintain predetermined plasma disopyramide concentrations. The calculated and observed disopyramide concentrations were in close agreement. In the 12 patients studied, at any given total disopyramide plasma concentration, there was an approximately twofold range in the fraction of disopyramide unbound to plasma proteins. Mean plasma protein binding data are therefore of little value in a given patient for predicting free disopyramide concentrations from measurements of total disopyramide concentration. Difficulties in the clinical management of patients receiving disopyramide, resulting from the nonlinear disposition of the usually measured total disopyramide concentrations, are discussed.

Key words

nonlinear disposition plasma protein binding disopyramide 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. E. Ranney, R. R. Dean, A. Karim, and F. Radzialowski. Disopyramide phosphate: Pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent.Arch. Int. Pharmacodyn. Ther. 191:162–188 (1971).PubMedGoogle Scholar
  2. 2.
    A. Karim. The pharmacokinetics of norpace.Angiology 26:85–98 (Suppl. 1, Part 2) (1975).PubMedGoogle Scholar
  3. 3.
    J. W. Ward and S. R. Kinghorn. The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.J. Int. Med. Res. 4:49–53 (Suppl. 1) (1976).PubMedGoogle Scholar
  4. 4.
    R. E. Rangno, W. Warica, R. I. Ogilvie, and E. Bridges. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.J. Int. Med. Res. 4:54–58 (Suppl. 1) (1976).PubMedGoogle Scholar
  5. 5.
    J. Hulting and S. Rosenhamer. Antiarrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmias.J. Int. Med. Res. 4:90–95 (Suppl. 1) (1976).PubMedGoogle Scholar
  6. 6.
    J. DeGraeve, P. Kremers, and J. E. Sielen. Etude pharmacocinetique et metabolique comparative de la disopyramide administree par voie orale et intraveineuse.Therapie 32:195–204 (1977).Google Scholar
  7. 7.
    P. H. Hinderling and E. R. Garrett. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.J. Pharmacokin. Biopharm. 4:199–230 (1976).CrossRefGoogle Scholar
  8. 8.
    J. L. Cunningham, D. D. Shen, I. Shudo, and D. L. Azarnoff. The effects of urinepH and plasma protein binding on the renal clearance of disopyramide.Clin. Pharmacokin. 2:373–383 (1977).CrossRefGoogle Scholar
  9. 9.
    P. J. Meffin, S. R. Harapat, and D. C. Harrison. High-pressure liquid Chromatographic analysis of drugs in biological fluids. III. Analysis of disopyramide and its non-N-dealkylated metabolite in plasma and urine.J. Chromatog. 132:503–510 (1977).CrossRefGoogle Scholar
  10. 10.
    J. G. Wagner. A safe method for rapidly achieving plasma concentration plateaus.Clin. Pharmacol. Ther. 16:691–700 (1974).PubMedGoogle Scholar
  11. 11.
    J. G. Wagner. Linear pharmacokinetic equations attaining direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.J. Pharmacokin. Biopharm. 4:443–66 (1976).CrossRefGoogle Scholar
  12. 12.
    S. Knott and D. Reece. Model Lab Users Documentation, Division of Computer Research Technology Report, National Institutes of Health, Bethesda, Md. September (1971).Google Scholar
  13. 13.
    H. Boxenbaum, S. Riegelman, and R. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokin. Biopharm. 2:123–148 (1974).CrossRefGoogle Scholar
  14. 14.
    B. B. Brodie, E. W. Lowman, J. J. Burns, P. R. Lee, T. Chenkin, A. Goldman, M. Weiner, and J. M. Steele. Observations on the antirheumatic and physiologic effects of phenyl-butazone (butazolidin) and some comparisons with cortisone.Am. J. Med. 16:181–190 (1954).PubMedCrossRefGoogle Scholar
  15. 15.
    R. Runkel, E. Forchielli, H. Sevelius, M. Chaplin, E. Segre. Nonlinear plasma level response to high doses of naproxen.Clin. Pharmacol. Ther. 15:261–266 (1974).PubMedGoogle Scholar
  16. 16.
    G. T. Tucker, R. N. Boyes, P. O. Bridenbaugh, and D. C. Moore. Binding of amide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties and anesthetic activity.Anesthesiology 32:287–303 (1970).CrossRefGoogle Scholar
  17. 17.
    J. Koch-Weser and E. M. Sellers. Binding of drugs to serum albumin.New Engl. J. Med. 294:311–316 (1976).PubMedCrossRefGoogle Scholar
  18. 18.
    D. C. Harrison, P. J. Meffin, and R. A. Winkle. Clinical pharmacokinetics of antiarrhythmic drugs.Prog. Cardiovasc. Dis. 20:217–242 (1977).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1979

Authors and Affiliations

  • Peter J. Meffin
    • 1
  • Edward W. Robert
    • 1
  • Roger A. Winkle
    • 1
  • Sandra Harapat
    • 1
  • Flora A. Peters
    • 1
  • Donald C. Harrison
    • 1
  1. 1.Pharmacokinetics Laboratory, Division of CardiologyStanford University School of MedicineStanford

Personalised recommendations